Berlin, Germany

Samuel M Rapoport

This inventor holds 1 USPTO granted patent. Top assignee: Veb Arzneimittelwerk Dresden. Active years: 1987.


% Patents Active = 100.0

Average Co-Inventor Count = 8.0

ph-index = 1

Forward Citations = 4(Granted Patents)


Company Filing History:


Years Active: 1987

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Samuel M Rapoport: Innovator in Pharmaceutical Chemistry

Introduction

Samuel M Rapoport is a notable inventor based in Berlin, Germany. He has made significant contributions to the field of pharmaceutical chemistry, particularly through his innovative work on hydroxamic acids. His research has led to the development of compounds with valuable pharmacological properties.

Latest Patents

Rapoport holds a patent for "Hydroxamic acid and pharmaceutical preparations containing the same." This patent discloses new .omega.(2'-naphthoxy)-alkylhydroxamic acids and a process for their production. The new compounds exhibit antiasthmatic and other pharmacologically valuable characteristics. They are synthesized by reacting the corresponding carboxylic acid ester or amide with hydroxylamine or its salt under specific conditions, resulting in compounds of Formula I.

Career Highlights

Samuel M Rapoport is associated with Veb Arzneimittelwerk Dresden, where he has contributed to various research projects. His work has been instrumental in advancing the understanding of hydroxamic acids and their applications in medicine.

Collaborations

Rapoport has collaborated with notable colleagues such as Tankred Schewe and Thomas Strumpf. Their combined expertise has furthered the development of innovative pharmaceutical solutions.

Conclusion

Samuel M Rapoport's contributions to pharmaceutical chemistry, particularly through his patent on hydroxamic acids, highlight his role as an influential inventor in the field. His work continues to impact the development of valuable medical treatments.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…